Neuroprotective peptide drug delivery and development: Potential new therapeutics

Trends in Neurosciences

Volumn 24, Issue 12, 2001, Pages 700-705

  Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEW DRUG; OXYTOCIN; PEPTIDE HORMONE; VASOPRESSIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG TRANSPORT; MEDICAL RESEARCH; MEMBRANE TRANSPORT; NEUROPROTECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS;

EID: 0035576894     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)01931-7     Document Type: Review

References (70)

1. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: Review and current status
2. The parkinsonian models: Invertebrates to mammals
3. Optimal pregnancy outcome in a minimal-stimulation in vitro fertilization program
4. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer
5. A peptide as a possible transmitter in sympathetic ganglia of the frog
6. Intranasal gonadotropin-releasing hormone (GnRH) therapy for men with idiopathic infertility: GnRH stimulation test may predict response to treatment
7. Vasopressin and vasopressin analogues for treatment of memory disorders in clinical practice
8. Aqueous vasopressin infusion during chemotherapy in patients with diabetes insipidus
9. Memory deficit in rats with hereditary diabetes insipidus
10. Neuromodulation of memory in the hippocampus by vasopressin
11. History and use of oxytocics
12. Social amnesia in mice lacking the oxytocin gene
13. The neurobiology of attachment
14. Pharmaceutical VIP: Prospects and problems
15. Backbone cyclic peptide antagonists, derived from the insect pheromone biosynthesis activating neuropeptide, inhibit sex pheromone biosynthesis in moths
16. Recent developments in computational proteomics
17. Target-oriented and diversity-oriented organic synthesis in drug discovery
18. Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier
19. Differential transport of rat and human interleukin-1alpha across the blood-brain barrier and blood-testis barrier in rats
20. Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat
21. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat
22. Central analgesic actions of loperamide following transient permeation of the blood-brain barrier with cereport (RMP-7)
23. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system
24. Delivery of peptides and proteins through the blood-brain barrier
25. Acute application of NGF increases the firing rate of aged rat basal forebrain neurons
26. NGF and anti-transferrin receptor antibody conjugate: Short and long-term effects on survival of cholinergic neurons in intraocular septal transplants
27. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells
28. A non-invasive transport system for GDNF across the blood-brain barrier
29. TAT-mediated protein transduction into mammalian cells
30. Manipulating neuro-peptidergic pathways in humans: A novel approach to neuropharmacology?
31. Improvements in the selective perception and training of rats using an original analog of the C-terminal fragment of vasopressin
32. Persistent central diabetes insipidus presenting in a very low birth weight infant successfully managed with intranasal dDAVP
33. Peptide T and glucose metabolism in AIDS dementia complex
34. Quantitative analysis of the olfactory pathway for drug delivery to the brain
35. Delivery of insulin-like growth factor-1 to the brain and spinal cord along olfactory and trigeminal pathways following intranasal administration: A noninvasive method for bypassing the blood-brain barrier
36. The biopharmaceutical aspects of nasal mucoadhesive drug delivery
37. Preparation of desmopressin-containing liposomes for intranasal delivery
38. Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist
39. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
40. Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats
41. VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death
42. Superactive lipophilic peptides discriminate multiple VIP receptors
43. Novel neuroprotective strategy for Alzheimer's disease: Inhalation of a fatty neuropeptide
44. Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth
45. Interaction of lipophilic VIP1/PACAP and VIP2/PACAP receptors
46. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implication for early treatment of Alzheimer's disease
47. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives
48. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design
49. Identification of VIP/PACAP receptors on astrocytes using antisense oligodeoxynucleotides
50. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide
51. A femtomolar-acting neuroprotective peptide
52. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide
53. Cloning and characterization of the human activity-dependent neuroprotective protein
54. Activity-dependent neurotrophic factor: Structure-activity relationships of femtomolar-acting peptides
55. A new concept in neuroprotection
56. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation
57. A novel peptide (NAP) prevents death in enriched neuronal cultures
58. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress
59. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease
60. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome
61. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives
62. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury mice
63. Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a watermaze
64. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death
65. Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9
66. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor
67. A glia-derived signal regulating neuronal differentiation
68. Activity dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures
69. Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects
70. Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration